Xtant Medical Holdings, a global regenerative medicine company specializing in orthobiologics for orthopedic and neurosurgical specialists, has entered a partnership with B2i Digital to enhance investor understanding of its platform and long-term value. This collaboration aims to provide centralized, investor-focused content targeting both retail and institutional audiences, leveraging B2i Digital's expertise in digital communication and investor relations.
David Shapiro, CEO of B2i Digital, emphasized that featuring Xtant Medical at this juncture is significant due to the company's comprehensive coverage of major orthobiologic categories and its trajectory of revenue growth. The partnership is designed to articulate Xtant Medical's growth story and the intrinsic value of its biologics platform to the investment community, as stated by Xtant Medical CEO Sean Browne. The company's vertically integrated model spans bone-healing grafts to amnion products, supported by a robust R&D pipeline.
Xtant Medical reported fiscal year 2024 revenue of $117.5 million, a 29% increase over the prior year, reflecting strong business fundamentals. The company holds extensive market access through 450 integrated delivery network contracts and a network of over 670 independent distributors, positioning it strongly in the $2.5 billion U.S. orthobiologics market, which is part of the larger $10.1 billion global spine market. This partnership underscores the company's commitment to transparent communication as it continues to expand its footprint in the medical technology sector.
